Many targets for solid tumours in clinical trials for ovarian cancer have relied on well-established tumour-associated antigens, e.g., HER2, WT1, NY-ESO-1, and p53, but these are not frequently found to be presented on MHC molecules on ovarian cancer cells. Here, TP53 is linked to ovarian cancer.